glp-1 news today 2025 november 5 Novo Nordisk, Lilly strike deal with Trump to slash weight-loss drug prices A second helping of weight-loss

Patients allege that the company marketed Trulicity as a safe option for controlling blood sugar levels but failed to warn about the increased risk of serious health issues

Many patients report changes in their food preferences and cravings when taking GLP-1 medications, though individual experiences vary considerably

There is little to no data or direct research on whether microdosing GLP-1s leads to meaningful weight loss or long-term weight management, Dr

Patients with obesity, or overweight plus a weight-related condition, on the 2.4 mg maintenance dose lost 15% on average (vs ~2%)

Ralston J, Nugent R

(Compounded Semaglutide Products), Report #7488, NAD/CARU Case Reports (November 2025)